| Identification | Back Directory | [Name]
Thiazovivin | [CAS]
1226056-71-8 | [Synonyms]
Thiazovivin
Thiazovivin, >=98%
N-Benzyl-2-(pyrimidin-4-ylamino)thiazole-4-carboxamide
N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide
Thiazovivin
N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide
N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide Thiazovivin | [EINECS(EC#)]
808-340-9 | [Molecular Formula]
C15H13N5OS | [MDL Number]
MFCD16495823 | [MOL File]
1226056-71-8.mol | [Molecular Weight]
311.362 |
| Chemical Properties | Back Directory | [density ]
1.379 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [color ]
, white to beige to brown | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| Hazard Information | Back Directory | [Uses]
A compound that improves the survival of human embryonic stem cells (hESCs) upon trypsinization. In combination with ALK5 (TGFβ receptor) inhibitor SB-431542 and MEK inhibitor PD-0325901 (P217450), Thiazovivin promotes the transformation of fibroblasts into stem cells with a 200-fold efficiency over the classic method | [Biochem/physiol Actions]
Thiazovivin is an inhibitor of Rho associated coiled-coil containing protein kinase (ROCK). In vitro studies prove that thiazovivin is efficient in stimulating better morphology, expression of ionic transporter and protein involved in cell adhesion. | [storage]
-20°C | [References]
1) Lin et al. (2009), A chemical platform for improved induction of iPSC; Nature Methods, 6 805
2) Zhu et al. (2012), Direct conversion of porcine embryonic fibroblasts into adipocytes by chemical molecules; Cell Reprogram., 14 99 |
| Questions And Answer | Back Directory | [Description]
Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation. | [In vitro]
Although displaying little impact on cell proliferation, Thiazovivin treatment significantly enhances the survival of human embryonic stem cells (hESCs) after enzymatic dissociation more than 30-fold, while homogenously maintaining pluripotency with the characteristic colony morphology, expression of typical pluripotency markers such as alkaline phosphatase (ALP), and normal karyotype. Dissociated hESCs treated with Thiazovivin display dramatically increased adhesion to matrigel-or laminin-coated plates but not to gelatin-coated plates within a few hours. Thiazovivin treatment increases cell-ECM adhesion-mediated β1 integrin activity, which synergizes with growth factors to promote cell survival. In addition to activating integrin, Thiazovivin but not Tyrintegin (Ptn) protects hESCs from death in the absence of ECM in suspension through E-cadherin-mediated cell-cell interaction. Thiazovivin treatment potently inhibits endocytosis of E-cadherin, consequently stabilizing E-cadherin on the cell surface and leading to reestablishment of cell-cell interaction, which is essential for hESC survival in ECM-free conditions. Thiazovivin but not Tyrintegin (Ptn) at 2 μM inhibits Rho-associated kinase (ROCK) activity and protects hESCs at a similar level as the widely used selective ROCK inhibitor Y-27632 at 10 μM, suggesting that Rho-ROCK signaling regulates cell-ECM and cell-cell adhesion. [1] Thiazovivin at 1 μM increases the reprogramming efficiency of CB mononuclear cells to induced pluripotent stem cells (iPSCs) by more than 10 times. |
|
|